# US 2025/0179068 A1 · Synthesis of kras g12c inhibitor compound

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0179068 A1
- Document ID: US20250179068A1
- Status: Published application
- Kind: A1
- Application number: 18/988,163
- Filed: 2024-12-19
- Published: 2025-06-05
- Earliest claimed: 2019-11-14
- Assignees: Amgen Inc.
- Applicants: Amgen Inc.
- Inventors: Andrew T. PARSONS; Matthew G. BEAVER
- Web page: https://patentgrep.com/patent/US20250179068A1

## CPC

- C07D 471/04: Ortho-condensed systems
- C07F 5/05: Cyclic compounds having at least one ring containing boron but no carbon in the ring
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2,2′,2″-(1,3,5,2,4,6-trioxatriborinane-2,4,6-triyl)tris(3-fluorophenol), useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.

## Claims

### Claim 1

A process of preparing a compound of Formula (6A):
comprising admixing (2-fluoro-6-methoxyphenyl) boronic acid with BBr3 in at least one solvent to provide the compound of Formula (6A).

### Claim 2 (depends on 1)

The process of claim 1, wherein 1.0 molar equivalents of the (2-fluoro-6-methoxyphenyl) boronic acid are admixed with 1.2 molar equivalents of the BBr3.

### Claim 3 (depends on 1)

The process of claim 1, comprising preparing a first mixture of the BBr3 in the at least one solvent before admixing the (2-fluoro-6-methoxyphenyl) boronic acid and the BBr3.

### Claim 4 (depends on 3)

The process of claim 3, comprising preparing a second mixture of the (2-fluoro-6-methoxyphenyl) boronic acid in the at least one solvent before admixing the (2-fluoro-6-methoxyphenyl) boronic acid and the BBr3.

### Claim 5 (depends on 4)

The process of claim 4, comprising adding the second mixture to the first mixture while maintaining the temperature of the at least one solvent in the first mixture between −15° C. and −25° C.

### Claim 6 (depends on 5)

The process of claim 5, wherein the (2-fluoro-6-methoxyphenyl) boronic acid and the BBr3 are maintained in the combined first and second mixture for approximately 2 hours.

### Claim 7 (depends on 1)

The process of claim 1, wherein the at least one solvent is dichloromethane.

### Claim 8 (depends on 1)

The process of claim 1, wherein the process further comprises a process of making (2-fluoro-6-methoxyphenyl) boronic acid, comprising:
(a) a first step of admixing a first base, a secondary amine base and a catalyst in a solvent to prepare a first mixture;
(b) a second step of admixing 3-fluoroanisole to the first mixture to prepare a second mixture; and
(c) a third step of admixing a reagent to the second mixture to form the (2-fluoro-6-methoxyphenyl) boronic acid.

### Claim 9 (depends on 8)

The process of claim 8, wherein the first base is n-butyl lithium.

### Claim 10 (depends on 9)

The process of claim 9, wherein the secondary amine base is diisopropylamine.

### Claim 11 (depends on 10)

The process of claim 10, wherein the catalyst is triethylamine hydrochloride.

### Claim 12 (depends on 11)

The process of claim 11, wherein the reagent is triethyl borate.

### Claim 13 (depends on 12)

The process of claim 12, wherein the first, second and third steps are conducted at −70° C.

### Claim 14

A process of preparing a compound of Formula 7
comprising admixing a compound of Formula (6A):
with a compound of Formula (6):
in the presence of a catalyst and potassium acetate to form the compound of Formula (7).

### Claim 15 (depends on 14)

The process of claim 14, wherein the catalyst is dichlorobis(diphenylphosphinophenyl)ether palladium (II) (Pd(dpePhos)Cl2).

### Claim 16 (depends on 15)

The process of claim 15, wherein 1.0 molar equivalents of the compound of Formula (6) are admixed with 0.5 molar equivalents of the compound of Formula (6A).

### Claim 17 (depends on 15)

The process of claim 15, wherein 1.0 molar equivalents of the compound of Formula (7) are admixed with 0.003 molar equivalents of Pd(dpePhos)Cl2.

### Claim 18 (depends on 17)

The process of claim 17, wherein 1.0 molar equivalents of the compound of Formula (7) are admixed with 2.0 molar equivalents of potassium acetate.

### Claim 19 (depends on 18)

The process of claim 18, wherein the compound of Formula (7), the compound of Formula (6A), the Pd(dpePhos)Cl2, and the potassium acetate are admixed in a solvent, wherein the solvent comprises 2-methyl tetrahydrofuran.

### Claim 20 (depends on 19)

The process of claim 19, wherein the solvent further comprises water.

### Claim 21 (depends on 20)

The process of claim 20, wherein the solvent is maintained at 75±5° C.

### Claim 22 (depends on 1)

A process of preparing a compound of Formula (9):
or a pharmaceutically acceptable salt thereof, comprising the process of claim 1.

### Claim 23 (depends on 14)

A process of preparing a compound of Formula (9):
or a pharmaceutically acceptable salt thereof, comprising the process of claim 14.

### Claim 24 (depends on 23)

The process of claim 23, further comprising admixing the compound of Formula (7) with trifluoroacetic acid to provide a compound of Formula (8):

### Claim 25 (depends on 24)

The process of claim 24, further comprising admixing the compound of Formula (8) with acryloyl chloride to afford the compound of Formula (9).
